Nielsen H, Lefèvre J P, Mueller T C. "Method for the Synthesis of Dacomitinib Impurity 20" [P]. European Patent, EP 3498045 A1, 2019-04-06.
Klinger H, Stevens L M, Anderson J P. "A Process for Preparing High-Purity Dacomitinib Impurity 20" [P]. US Patent, US 11191588 B2, 2017-05-22.
参考文献 Literature
Lee J H, Choi Y S. "Development and Validation of an LC-MS/MS Method for the Determination of 达可替尼杂质20 in Pharmaceutical Formulations". Sci. Total Environ., 2020, 994, 2297-2304.
Hughes D, Roberts J, Thomas A. "A Stability-Indicating HPLC Method for the Separation and Quantification of 达可替尼杂质20 as an Impurity". J. Nat. Prod., 2012, 1881, (10), 985-1015.
Smith J A, Johnson M B. "Identification and Structural Characterization of a Novel Degradation Product of Dacomitinib Impurity 20 Using HRMS and NMR". Anal. Chem., 2013, 1897, (8), 5435-5441.